2 ms·
I know this company well and knew this was going to become a PR issue. Aimmune's product is just purified peanut flour. Convincing everyone it's worth thousan
by refurb 7y ago
I know this company well and knew this was going to become a PR issue. Aimmune's product is just purified peanut flour. Convincing everyone it's worth thousands (to tens of thousands) of dollars is going to be tough.
That said, you're not paying for the peanut flour, you're paying for the comprehensive set of data the company had to develop to prove the product actually works.
Just rough numbers, a phase 3 clinical trials costs about $15K per patient per year. Aimmune ran a year long trial with 1000 patients (from clinicaltrials.gov), so the trial alone cost them almost $160M dollars. Add in manufacturing regulations, etc, you can understand why they raised $400M over the past 8 years since they were formed.[1]
The other thing to keep in mind is the pharmacoeconomic arguments. If insurance companies are paying thousands of dollars each time a child goes to the ER for a allergic response, pay $10,000 for this drug to reduce those may make total sense.
Also interesting that this article comes out the same day the stock is halted because the FDA review committee is meeting. You can peruse the briefing document to see what they'll be discussing.[2]
[1]https://www.crunchbase.com/organization/allergen-research-corporation https://www.crunchbase.com/organization/allergen-research-co...
[2]https://www.fda.gov/media/130654/download https://www.fda.gov/media/130654/download